Viatris gains as UBS upgrades to buy on outlook and pipeline
I'm PortAI, I can summarize articles.
Shares of Viatris (VTRS) rose after UBS upgraded the stock to Buy from Neutral, increasing the price target from $8 to $11 per share. Analyst Ashwani Verma highlighted a positive growth outlook and a robust drug pipeline, adjusting estimates accordingly. He noted Viatris trades at a favorable valuation of 5x consensus EPS estimates for 2027. Overall, Wall Street maintains a bullish stance on Viatris, with an average analyst rating of Buy, while Seeking Alpha rates it as a Hold.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments